研究者業績

阿部 和穂

アベ カズホ  (ABE KAZUHO)

基本情報

所属
武蔵野大学 薬学部 薬学科 教授
学位
博士(東京大学)
修士(東京大学大学院)

J-GLOBAL ID
200901002682792583
researchmap会員ID
1000013647

外部リンク

研究キーワード

 2

委員歴

 2

論文

 3
  • Hiroko Ushikubo, Sayaka Watanabe, Yui Tanimoto, Kazuho Abe, Aiki Hiza, Takahiro Ogawa, Tomohiro Asakawa, Toshiyuki Kan, Tatsuhiro Akaishi
    NEUROSCIENCE LETTERS 513(1) 51-56 2012年3月  査読有り
    The natural flavonoid fisetin (3,3',4',7-tetrahydroxyflavone) is neurotrophic and prevents fibril formation of amyloid beta protein (A beta). It is a promising lead compound for the development of therapeutic drugs for Alzheimer's disease. To find even more effective drugs based on the structure of fisetin, we synthesized a series of fisetin analogues lacking the 7-hydroxyl group and compared their effects on A beta fibril formation determined by the thioflavin T fluorescence assay. 3,3',4'-Trihydroxyflavone and 3',4'-dihydroxyflavone inhibited A beta fibril formation more potently than fisetin or 3',4',7-trihydroxyflavone, suggesting that the 7-hydroxy group is not necessary for anti-amyloidogenic activity. 3,3',4',5'-Tetrahydroxyflavone and 3',4',5'-trihydroxyflavone inhibited A beta fibril formation far more potently than 3,3',4'-trihydroxyflavone and 3',4'-dihydroxyflavone, suggesting that 3',4',5'-trihydroxyl group of the B ring is crucial for the anti-amyloidogenic activity of flavonoids. Based on the structure-activity relationship, we synthesized 3,3',4',5,5'-pentahydroxyflavone, and confirmed that this compound is the most potent inhibitor of A beta fibril formation among fisetin analogues that have been tested. Cytotoxicity assay using rat hippocampal neuron cultures demonstrated that A beta preincubated with 3,3',4',5,5'-pentahydroxyflavone was significantly less toxic than A beta preincubated with vehicle. 3,3',4',5,5'-Pentahydroxyflavone could be a new therapeutic drug candidate for the treatment of Alzheimer's disease. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
  • Qi Chen, Marguerite Prior, Richard Dargusch, Amanda Roberts, Roland Riek, Cedric Eichmann, Chandramouli Chiruta, Tatsuhiro Akaishi, Kazuho Abe, Pamela Maher, David Schubert
    PLOS ONE 6(12) e27865 2011年12月  査読有り
    Currently, the major drug discovery paradigm for neurodegenerative diseases is based upon high affinity ligands for single disease-specific targets. For Alzheimer's disease (AD), the focus is the amyloid beta peptide (A beta) that mediates familial Alzheimer's disease pathology. However, given that age is the greatest risk factor for AD, we explored an alternative drug discovery scheme that is based upon efficacy in multiple cell culture models of age-associated pathologies rather than exclusively amyloid metabolism. Using this approach, we identified an exceptionally potent, orally active, neurotrophic molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model.
  • 115(2) 254-257 2011年2月  査読有り
    著者らは、以前の研究において南天実エキスがモルモット気管平滑筋を弛緩させることを見出していたが、本研究では南天実に含まれる有効成分のヒゲナミンとナンテニンがどのように関与するかを検討し、ナンテニンがβ受容体刺激作用により素早い弛緩を、ヒゲナミンがCa拮抗作用により緩やかな弛緩を引き起こすことを明らかにした。

MISC

 131
  • M. Tsukiyama, T. Ueki, Y. Yasuda, H. Kikuchi, T. Akaishi, H. Okumura, K. Abe
    Planta Med., 75(13) 1393-1399 2009年10月  
    モルモット気管平滑筋を弛緩させる南天実エキスの活性成分の同定を試み、それがヒゲナミンであり、β<SUB>2</SUB>受容体刺激によって気管拡張をおこすことを解明した。
  • Kazuho Abe, Taiki Fujimoto, Tatsuhiro Akaishi, Miwa Misawa
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY 33(3) 552-556 2009年4月  
    We have previously found that the induction of hippocampal long-term potentiation (LTP) is modulated by neuron activities in the basolateral amygdala (BLA). However, little is known about what neurotransmitter system in the BLA contributes to modulation of hippocampal LTP. In the present study, we investigated possible involvement of BLA dopaminergic system in the induction of UP at the perforant path (PP)-dentate gyrus (DG) granule cell synapses of anesthetized rats. The induction of PP-DG LTP was significantly attenuated by intra-BLA injection of the D(1) receptor antagonist SCH23390 (2 or 6 nmol) or the D(2) receptor antagonists, chlorpromazine (30 or 100 nmol) or haloperidol (4.4 or 13.3 nmol). The effects of SCH23390 and haloperidol were abolished by concomitant intra-BLA injection of the D(1) receptor agonist SKF38393 (17 nmol) and the D(2) receptor agonist quinpirole (3 nmol), respectively. Furthermore, lesioning with 6-hydroxydopamine of the ventral tegmental area, the origin of the dopaminergic system projecting to the BLA, resulted in attenuated PP-DG LTP, which was restored by intra-BLA injection of SKF38393 or quipirole. These results suggest that the induction of PP-DG UP is promoted by the BLA dopaminergic system via both D(1) and D(2) receptors. (C) 2009 Elsevier Inc. All rights reserved.
  • Kazuho Abe, Taiki Fujimoto, Yoshiaki Niikura, Tatsuhiro Akaishi, Miwa Misawa
    EUROPEAN JOURNAL OF PHARMACOLOGY 606(1-3) 90-93 2009年3月  
    We have previously found that the induction of long-term potentiation in the synaptic pathway from the basolateral amygdala to the dentate gyros (BLA-DG LTP) is regulated by L-type Ca2+ channels, dopamine D-2 receptors and GABAergic inhibition. In the present study, we investigated possible relations among the three mechanisms by using anesthetized rats. Blockade of GABAergic inhibition with picrotoxin abolished both the inhibitory effect of the dopamine D-2 receptor antagonist chlorpromazine and the promoting effect of the dopamine D-2 receptor agonist quinpirole on the induction of BLA-DG LTP. However, the inhibitory effect of the L-type Ca2+ channel blocker verapamil on BLA-DG LTP was not affected by picrotoxin. These results suggest that the role of dopamine D-2 receptors in the induction of BLA-DG LTP is modulatory and depends on GABAergic inhibition, whereas the role of L-type Ca2+ channels is fundamental. (C) 2009 Elsevier B.V. All rights reserved.
  • Kazuho Abe, Taiki Fujimoto, Tatsuhiro Akaishi, Miwa Misawa
    NEUROSCIENCE LETTERS 451(1) 65-68 2009年2月  
    We have previously found that the induction of hippocampal long-term potentiation (LTP) is modulated by neuron activities in the basolateral amygdala (BLA). However, little is known about what neurotransmitter system in the BLA contributes to modulation of hippocampal LTP. In the present study, we investigated possible involvement of BLA serotonergic system in the induction of LTP at the perforant path (PP)-dentate gyrus (DG) granule cell synapses of anesthetized rats. The induction of PP-DG LTP was significantly inhibited by intra-BLA injection of the 5-HT2 receptor antagonist cinanserin (25-50 nmol), but not by intra-BLA injection of the 5-HT1.7 receptor antagonist methiothepin (50 nmol), the 5-HT3 receptor antagonist ondansetron (50 nmol) or the 5-HT4 receptor antagonist RS23597-190 (100 nmol). In addition, intra-BLA injection of the 5-HT2C receptor agonist MK212 (50 nmol) facilitated the induction of PP-DG LTP. These results suggest that the induction of PP-DG LTP is promoted by activation of 5-HT2C receptors in the BLA. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
  • Kazuho Abe, Yoshiaki Niikura, Taiki Fujimoto, Tatsuhiro Akaishi, Miwa Misawa
    NEUROPHARMACOLOGY 55(8) 1419-1424 2008年12月  
    We have previously found that synaptic pathway from the basolateral amygdala (BLA) to the dentate gyrus (DG) displays N-methyl-D-aspartate (NMDA) receptor-independent form of long-term potentiation (LTP), which should be a valuable model for elucidating neural mechanisms linking emotion and memory. To explore its cellular mechanisms, we investigated possible involvement of the beta-adrenergic, muscarinic cholinergic and dopaminergic systems on UP in this pathway of anesthetized rats. The induction of BLA-DG LTP was not affected by administration of the beta-adrenoceptor antagonist propranolol (50-150 nmol, i.c.v.), the muscarinic receptor antagonist scopolamine (2-6 mg/kg, i.p.), the cholinesterase inhibitor physostigmine (50 nmol, i.c.v.) or the dopamine D-1 receptor antagonist SCH23390 (100 nmol, i.c.v.), but Significantly inhibited by the dopamine D-2 receptor antagonists, chlorpromazine (15 nmol, i.c.v.) and haloperidol (0.15-0.5 mg/kg, i.p.), and significantly promoted by the dopamine D-2 receptor agonist quinpirole (78 nmol, i.c.v.). Furthermore, lesioning with 6-hydroxydopamine of the ventral tegmental area (VTA), the origin of mesolimbic dopaminergic neurons, resulted in attenuated BLA-DG LTP. These results Suggest that the D-2-dopaminergic system, but not the beta-adrenergic, muscarinic or D-1-dopaminergic system, is involved in the induction of BLA-DG LTR In addition, inhibition of BLA-DG UP by haloperidol or VIA lesion was abolished by blockade of GABAergic inhibition with picrotoxin. It is probable that the D-2-dopaminergic system promotes the induction of BLA-DG LTP by Suppressing GABAergic inhibition. (C) 2008 Elsevier Ltd. All rights reserved.

書籍等出版物

 24
  • 阿部和穂, 村上泰興, 鈴木順子 (担当:共著)
    評言社 2009年6月
    平成21年春に実施された94回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の作用に関する出題30問について解説を執筆した。
  • 阿部和穂, 三澤美和, 千葉義彦, 松岡隆, 砂金信義, 宇留野強, 小島周二 (担当:共著)
    評言社 2009年4月
    薬剤師国家試験ガイドラインの医療薬学・薬理学の分野について、2010年春の国家試験対策として必要な知識をまとめた参考書。当人は「中枢神経系に作用する薬物」「オータコイド」「病原生物に作用する薬物」などについて分担執筆した。
  • 阿部和穂, 村上泰興, 上田晴久 (担当:共著)
    評言社 2008年6月
    平成20年春に実施された93回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の作用に関する出題30問について解説を執筆した。
  • 阿部和穂, 三澤美和, 千葉義彦, 松岡隆, 砂金信義, 宇留野強, 小島周二 (担当:共著)
    評言社 2008年4月
    薬剤師国家試験ガイドラインの医療薬学・薬理学の分野について、2009年春の国家試験対策として必要な知識をまとめた参考書。当人は「中枢神経系に作用する薬物」「オータコイド」「病原生物に作用する薬物」などについて分担執筆した。
  • 阿部和穂, 村上泰興, 上田晴久 (担当:共著)
    評言社 2007年6月
    平成19年春に実施された92回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の作用に関する出題30問について解説を執筆した。